TRX WOUND CARE LIMITED

Active Leeds

Research and experimental development on biotechnology

0 employees website.com
Research and experimental development on biotechnology
T

TRX WOUND CARE LIMITED

Research and experimental development on biotechnology

Founded 13 Oct 2011 Active Leeds, England 0 employees website.com
Research and experimental development on biotechnology

Previous Company Names

TRX WOUNDCARE LIMITED 13 Oct 2011 — 18 Apr 2016
Accounts Submitted 20 Aug 2025 Next due 30 Sept 2026 4 months remaining
Confirmation Submitted 3 Nov 2025 Next due 27 Oct 2026 5 months remaining
Net assets £-22M £171K 2024 year on year
Total assets £7M £1M 2024 year on year
Total Liabilities £29M £2M 2024 year on year
Charges 6
6 outstanding

Contact & Details

Contact

Registered Address

Unit 3, Phoenix Court Lotherton Way Garforth Leeds LS25 2GY England

Full company profile for TRX WOUND CARE LIMITED (07809175), an active company based in Leeds, England. Incorporated 13 Oct 2011. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type Total Exemption Full
Next accounts 31 December 2025
Due by 30 September 2026 9 months

Balance Sheet & P&L (2014–2024)

Cash in Bank

N/A

Net Assets

-£21.99M

Decreased by £171.00k (-1%)

Total Liabilities

£29.34M

Increased by £1.59M (+6%)

Turnover

£1.70M

Increased by £600.00k (+55%)

Employees

N/A

Debt Ratio

399%

Decreased by 69 (-15%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
Dec Year End
2023
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Officers

Officers

1 active 2 resigned
Status
Jonathan Martin GlennDirectorBritishUnited Kingdom571 Apr 2020Active

Shareholders

Shareholders (1)

Tissue Regenix Limited
100.0%

Persons with Significant Control

Persons with Significant Control (1)

1 Active

Tissue Regenix Limited

United Kingdom

Active
Notified 6 Apr 2016
Nature of Control
  • Ownership Of Shares 75 To 100 Percent

Group Structure

Group Structure

TISSUE REGENIX LIMITED united kingdom
TRX WOUND CARE LIMITED Current Company

Charges

Charges

6 outstanding

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
5 Jan 2026MortgageMortgage Create With Deed With Charge Number Charge Creation Date
3 Nov 2025Confirmation StatementConfirmation statement made on 13 Oct 2025 with no updates
3 Nov 2025OfficersAppointment of Miss Kirsten Mary Lund as director on 16 Oct 2025
3 Nov 2025OfficersTermination of Daniel Ray Lee as director on 15 Oct 2025
11 Sept 2025OfficersAppointment of Mr Jay Charles Lecoque as director on 4 Sept 2025
5 Jan 2026 Mortgage

Mortgage Create With Deed With Charge Number Charge Creation Date

3 Nov 2025 Confirmation Statement

Confirmation statement made on 13 Oct 2025 with no updates

3 Nov 2025 Officers

Appointment of Miss Kirsten Mary Lund as director on 16 Oct 2025

3 Nov 2025 Officers

Termination of Daniel Ray Lee as director on 15 Oct 2025

11 Sept 2025 Officers

Appointment of Mr Jay Charles Lecoque as director on 4 Sept 2025

Recent Activity

Latest Activity

Mortgage Create With Deed With Charge Number Charge Creation Date

4 months ago on 5 Jan 2026

Confirmation statement made on 13 Oct 2025 with no updates

6 months ago on 3 Nov 2025

Appointment of Miss Kirsten Mary Lund as director on 16 Oct 2025

6 months ago on 3 Nov 2025

Termination of Daniel Ray Lee as director on 15 Oct 2025

6 months ago on 3 Nov 2025

Appointment of Mr Jay Charles Lecoque as director on 4 Sept 2025

8 months ago on 11 Sept 2025